BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 1283267)

  • 1. [Hodgkin's disease--an entity?].
    Hansmann ML
    Verh Dtsch Ges Pathol; 1992; 76():24-36. PubMed ID: 1283267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fascin, a sensitive new marker for Reed-Sternberg cells of hodgkin's disease. Evidence for a dendritic or B cell derivation?
    Pinkus GS; Pinkus JL; Langhoff E; Matsumura F; Yamashiro S; Mosialos G; Said JW
    Am J Pathol; 1997 Feb; 150(2):543-62. PubMed ID: 9033270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hodgkin's disease, lymphocyte predominance type, nodular--further evidence for a B cell derivation. L & H variants of Reed-Sternberg cells express L26, a pan B cell marker.
    Pinkus GS; Said JW
    Am J Pathol; 1988 Nov; 133(2):211-7. PubMed ID: 3263805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype.
    Delabie J; Vandenberghe E; Kennes C; Verhoef G; Foschini MP; Stul M; Cassiman JJ; De Wolf-Peeters C
    Am J Surg Pathol; 1992 Jan; 16(1):37-48. PubMed ID: 1728195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
    Miettinen M
    Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Light-chain mRNA in lymphocyte-predominant and mixed-cellularity Hodgkin's disease.
    von Wasielewski R; Wilkens L; Nolte M; Werner M; Georgii A
    Mod Pathol; 1996 Mar; 9(3):334-8. PubMed ID: 8685237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-bet, a T cell-associated transcription factor, is expressed in Hodgkin's lymphoma.
    Dorfman DM; Hwang ES; Shahsafaei A; Glimcher LH
    Hum Pathol; 2005 Jan; 36(1):10-5. PubMed ID: 15712176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas.
    Weiss LM; Warnke RA; Sklar J; Cleary ML
    N Engl J Med; 1987 Nov; 317(19):1185-9. PubMed ID: 3657890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lymphoid depletion type 4 Hodgkin disease. Anatomoclinical review of 35 cases].
    Eghbali H; Pétorin C; de Mascarel I; Trojani M; Hoerni-Simon G; Soubeyran P; Hoerni B
    Bull Cancer; 1994 Oct; 81(10):866-70. PubMed ID: 7734769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The relations between Hodgkin's and non-Hodgkin's lymphoma].
    Lennert K
    Arzneimittelforschung; 1987 Feb; 37(2A):255-9. PubMed ID: 3566873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic reticulum cell immunoreactivity for low-affinity nerve growth factor receptor in malignant lymphomas.
    Dorfman DM; Shahsafaei A
    Mod Pathol; 1996 Oct; 9(10):959-65. PubMed ID: 8902831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interrelationship of Hodgkin's disease and non-Hodgkin's lymphomas--lessons learned from composite and sequential malignancies.
    Jaffe ES; Zarate-Osorno A; Medeiros LJ
    Semin Diagn Pathol; 1992 Nov; 9(4):297-303. PubMed ID: 1480852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin's disease and large cell lymphomas.
    Massarelli G; Onida GA; Piras MA; Marras V; Mura A; Tanda F
    Anticancer Res; 1999; 19(5B):3933-8. PubMed ID: 10628334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demonstration of light chain mRNA in Hodgkin's disease.
    Hell K; Pringle JH; Hansmann ML; Lorenzen J; Colloby P; Lauder I; Fischer R
    J Pathol; 1993 Oct; 171(2):137-43. PubMed ID: 8283350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Histopathology of malignant lymphomas].
    Yamabe H
    Rinsho Byori; 1990 Apr; 38(4):386-9. PubMed ID: 2195192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies.
    Abele MC; Valente G; Kerim S; Navone R; Onesti P; Chiusa L; Resegotti L; Palestro G
    Haematologica; 1997; 82(3):281-5. PubMed ID: 9234572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma.
    Ko YH; Kim CW; Park CS; Jang HK; Lee SS; Kim SH; Ree HJ; Lee JD; Kim SW; Huh JR
    Cancer; 1998 Aug; 83(4):806-12. PubMed ID: 9708949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to differentiate between T-cell-rich B-cell lymphoma and lymphocyte-predominant Hodgkin's disease. Evidence for the value of MB1 and 4KB5 immunostaining.
    Schmidt U; Herbst J; Metz KA; Leder LD
    J Pathol; 1996 Jun; 179(2):138-44. PubMed ID: 8758204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphomas in Iran.
    Hashemi-Bahremani M; Parwaresch MR; Tabrizchi H; Gupta RK; Raffii MR
    Arch Iran Med; 2007 Jul; 10(3):343-8. PubMed ID: 17604472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell typing in lymphoproliferative disorders. Use of a sensitive hemadsorption technique for sections of normal and abnormal lymphoid tissue.
    Wood WG; Hood P; Rippey JH
    Am J Surg Pathol; 1981 Jun; 5(4):369-79. PubMed ID: 7023259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.